These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 3098183

  • 1. [In vitro enhancement of cytotoxicity of human peripheral blood lymphocytes with recombinant interleukin 2 and an interferon mixture (alpha + beta + gamma) against human colon carcinoma cell line SW1116].
    Kimoto Y.
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3419-26. PubMed ID: 3098183
    [Abstract] [Full Text] [Related]

  • 2. Impairment of helper T-cell function and lymphokine-activated killer cytotoxicity following severe head injury.
    Quattrocchi KB, Frank EH, Miller CH, Amin A, Issel BW, Wagner FC.
    J Neurosurg; 1991 Nov; 75(5):766-73. PubMed ID: 1833515
    [Abstract] [Full Text] [Related]

  • 3. [Comparative study of the activating effects of recombinant human interleukin 2 and interferon-gamma on cell-mediated cytotoxicity against renal cell carcinoma in vitro].
    Marumo K, Ueno M, Baba S, Muraki J, Deguchi N, Tazaki H.
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1825-9. PubMed ID: 3109327
    [Abstract] [Full Text] [Related]

  • 4. Eradication of cultured human melanoma cells by immune interferon and leukocytes.
    Tyring SK, Klimpel G, Brysk M, Gupta V, Stanton GJ, Fleischmann WR, Baron S.
    J Natl Cancer Inst; 1984 Nov; 73(5):1067-73. PubMed ID: 6436563
    [Abstract] [Full Text] [Related]

  • 5. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR, Kamber M, Peck R.
    Lymphokine Res; 1987 Nov; 6(3):215-27. PubMed ID: 3114569
    [Abstract] [Full Text] [Related]

  • 6. [Combined effect of human recombinant interferon alpha, beta and gamma on tumor cell growth and the cell cycle in vitro].
    Kondo H, Tanaka N, Naomoto Y, Orita K.
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1234-9. PubMed ID: 3107476
    [Abstract] [Full Text] [Related]

  • 7. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
    Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL.
    Cancer Res; 1988 Jul 01; 48(13):3875-81. PubMed ID: 3132324
    [Abstract] [Full Text] [Related]

  • 8. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
    Weiner LM, Moldofsky PJ, Gatenby RA, O'Dwyer J, O'Brien J, Litwin S, Comis RL.
    Cancer Res; 1988 May 01; 48(9):2568-73. PubMed ID: 3128400
    [Abstract] [Full Text] [Related]

  • 9. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 10. [Combined effect of interferons alpha, beta and gamma on tumor growth in vitro].
    Kimoto Y.
    Gan To Kagaku Ryoho; 1986 Feb 15; 13(2):302-7. PubMed ID: 3080965
    [Abstract] [Full Text] [Related]

  • 11. Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.
    Weiner LM, Steplewski Z, Koprowski H, Litwin S, Comis RL.
    Cancer Res; 1988 Feb 15; 48(4):1042-6. PubMed ID: 3123051
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effect of recombinant human interferon-beta and interferon-gamma in combination against human colon cancer cell line in vitro and in nude mice.
    Kondo H, Tanaka N, Naomoto Y, Orita K.
    Jpn J Cancer Res; 1987 Nov 15; 78(11):1258-65. PubMed ID: 3121561
    [Abstract] [Full Text] [Related]

  • 13. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
    Fujimiya Y, Suzuki Y, Katakura R, Miyagi T, Yamaguchi T, Yoshimoto T, Ebina T.
    Clin Cancer Res; 1997 Apr 15; 3(4):633-43. PubMed ID: 9815731
    [Abstract] [Full Text] [Related]

  • 14. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.
    Nedwin GE, Svedersky LP, Bringman TS, Palladino MA, Goeddel DV.
    J Immunol; 1985 Oct 15; 135(4):2492-7. PubMed ID: 3928750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Combined effect of human recombinant interferon-beta and interferon-gamma against an experimental model of peritonitis carcinomatosa in nude mice].
    Kondo H, Tanaka N, Naomoto Y, Orita K.
    Gan To Kagaku Ryoho; 1987 Jun 15; 14(6 Pt 1):1836-40. PubMed ID: 3109328
    [Abstract] [Full Text] [Related]

  • 19. Activation of human monocyte cytotoxicity by natural and recombinant immune interferon.
    Le J, Prensky W, Yip YK, Chang Z, Hoffman T, Stevenson HC, Balazs I, Sadlik JR, Vilcek J.
    J Immunol; 1983 Dec 15; 131(6):2821-6. PubMed ID: 6417232
    [Abstract] [Full Text] [Related]

  • 20. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells.
    Okabe M, Gomi K, Morimoto M, Nakamizo N.
    Jpn J Cancer Res; 1985 Jul 15; 76(7):608-17. PubMed ID: 3928557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.